Winner F A Plus Perijoo

Adult dosage

The dosage and infusion rate are determined based on the patient's fat removal capability, nitrogen and carbohydrate metabolism ability, and nutritional requirements, and the dosage and bag size are determined according to the patient’s condition and weight. Patients with normal nutritional status or mild metabolic stress should receive 0.10-0.15 g/kg of nitrogen (0.6-0.9 g/kg of amino acids) per day. Patients experiencing moderate to high metabolic stress may require

Children's dosage

Use in children is not recommended.

This medication must be used strictly according to a physician's instructions. If allergic reactions such as fever, chills, rash, or difficulty breathing occur during use, administration must be stopped immediately. Since precipitates may form when used with intravenous calcium-containing preparations, it should not be administered through the same infusion line, and the equipment should be cleaned thoroughly before infusion. Particular caution is needed for premature infants or low-birth-weight infants, as there have been reported deaths when administered to premature infants with severe respiratory diseases. This medication should not be administered to individuals with allergies to fish, eggs, soybeans, or peanuts, or to patients with specific conditions such as severe hyperlipidemia, liver dysfunction, blood coagulation disorders, or renal failure. Neonates should not be co-administered with Ceftriaxone, and patients with hypersensitivity to soybean oil or nuts also require caution. Patients with renal failure, diabetes, pancreatitis, or liver dysfunction that affect fat metabolism should be administered with care. This medication can cause side effects such as fever, constipation, nausea, diarrhea, headache, and itching, as well as symptoms due to fat overload syndrome or amino acid overadministration. Patient condition should be closely monitored at the start of administration, and blood electrolytes and fluid status should be maintained normal. To reduce the risk of infection, aseptic procedures should be followed diligently, and the blood triglyceride levels should be periodically checked to prevent overdose during administration. During long-term administration, careful attention should also be paid to trace element balance, and it should not be administered simultaneously with blood. Regular monitoring of blood glucose, electrolytes, and liver function tests should be conducted, and patients with renal failure must manage phosphate and potassium intake. Patients with poor nutritional status should have fluid shifts and electrolyte changes closely observed, and administration should be started gradually. Patients with hyperglycemia may require insulin administration, and signs of phlebitis should be checked daily during peripheral venous infusion. This medication is not appropriate for children under 2 years of age, and there is insufficient safety data for pediatric use. Patients at risk of fat overload should check plasma lipid levels and adjust dosages as necessary. There are no safety data for use during pregnancy and lactation, so it should only be used when the therapeutic benefits outweigh the risks. Blood tests may be affected by administration, so blood tests should be performed 5-6 hours after administration. In case of overdose, the infusion rate should be slowed or stopped, and appropriate treatment should be received based on symptoms. Do not use if the packaging is damaged or if the solution is cloudy or separated, and maintain aseptic conditions during administration. This medication should be stored at a temperature between 1-30℃, avoiding freezing. It's safest to use immediately after mixing and store at 2-8℃ for use within 24 hours.

Serious side effects

Urticaria, rash, difficulty breathing, fat overload syndrome (hyperlipidemia, fever, jaundice, liver enlargement, spleen enlargement, anemia, thrombocytopenia, coagulation disorders, coma), anaphylactic reactions, reported deaths due to pulmonary vascular lipid accumulation, thrombophlebitis, need for insulin administration due to hyperglycemia, severe allergic reactions.

Mild side effects

• Fever
• constipation
• nausea
• diarrhea
• vomiting
• abdominal distension
• dizziness
• headache
• itching
• nausea

This medication should be stored in a sealed container to protect it from air and moisture, and it is safest to store at room temperature between 1°C and 30°C. Proper storage will help maintain the effectiveness of the medication and prevent deterioration.

Appearance

This medication consists of three compartments, which are divided into an internal bag and external packaging, with an oxygen absorber pouch in between. Each compartment contains glucose solution, amino acids, and electrolyte solution, and

Package unit

240mL (A Solution: 119mL, B Solution: 90mL, C Solution: 31mL)/pack, 382mL (A Solution: 189mL, B Solution: 143mL, C Solution: 50mL)/pack, 505mL (A Solution: 250mL, B Solution: 189mL, C Solution: 66mL)/pack, 733mL (A Solution: 363mL, B Solution: 274mL, C Solution: 96mL)/pack, 1085mL (A Solution: 537mL, B Solution: 406mL, C Solution: 142mL)